Advanced Oncotherapy PLC (LON:AVO) insider Steve Myers OBE bought 400,000 shares of the firm’s stock in a transaction that occurred on Monday, May 15th. The stock was bought at an average cost of GBX 26 ($0.34) per share, for a total transaction of £104,000 ($134,245.51).

Shares of Advanced Oncotherapy PLC (LON:AVO) opened at 26.50 on Wednesday. The firm’s 50-day moving average price is GBX 27.48 and its 200-day moving average price is GBX 57.12. The company’s market capitalization is GBX 15.03 million. Advanced Oncotherapy PLC has a 12-month low of GBX 20.18 and a 12-month high of GBX 209.88.

Insider Buying and Selling by Quarter for Advanced Oncotherapy PLC (LON:AVO)

TRADEMARK VIOLATION NOTICE: This news story was posted by American Banking News and is owned by of American Banking News. If you are accessing this news story on another website, it was stolen and republished in violation of US and international trademark & copyright legislation. The legal version of this news story can be viewed at https://www.americanbankingnews.com/2017/05/17/advanced-oncotherapy-plc-avo-insider-buys-104000-in-stock.html.

Separately, Beaufort Securities reaffirmed a “speculative buy” rating on shares of Advanced Oncotherapy PLC in a report on Tuesday, January 24th.

Advanced Oncotherapy PLC Company Profile

Advanced Oncotherapy Plc is focused on providing radiotherapy systems for cancer treatment through the use of a proton therapy technology. The Company is engaged in development and then building of the Linac Image Guided Hadron Technology (LIGHT) proton beam cancer therapy device and management of healthcare related property.

Receive News & Ratings for Advanced Oncotherapy PLC Daily - Enter your email address below to receive a concise daily summary of the latest news and analysts' ratings for Advanced Oncotherapy PLC and related companies with MarketBeat.com's FREE daily email newsletter.